Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 2/20 | 0.48 |
| ▸ | LYN | P07948 | 2/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.47 |
| ▸ | TNF | P01375 | 5/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.47 |
| ▸ | HCK | P08631 | 2/20 | 0.47 |
| ▸ | CIT | O14578 | 1/20 | 0.47 |
| ▸ | MUSK | O15146 | 1/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | STK10 | O94804 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081362 | 0.85 | MAPK14 (0.65) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL6807983 | 0.81 | ABL1 (0.61) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL6735307 | 0.80 | ABL1 (0.56) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4081823 | 0.80 | MAPK14 (0.68) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL6732717 | 0.80 | ABL1 (0.74) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL6807988 | 0.78 | ABL1 (0.51) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL6913451 | 0.76 | MAPK14 (0.51) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL5306366 | 0.75 | MAPK14 (0.55) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4081991 | 0.75 | ABL1 (0.61) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4091709 | 0.74 | MAPK14 (0.65) | SRCABL1RAF1LYNMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040033222-A1 | Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033222-A1 | Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors | TFPI2, TFPI, PLG | SRC 2036/4885ABL1 2261/4885RAF1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.